Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
David Niklas Springer, Michael Bauer, Iris Medits, Jeremy V. Camp, Stephan W. Aberle, Clemens Burtscher, Eva Höltl, Lukas Weseslindtner, Karin Stiasny, Judith H. Aberle
Abstract
We report SARS-CoV-2 neutralizing antibody titers in sera of triple-vaccinated individuals who received a booster dose of an original monovalent or a bivalent BA.1- or BA.4/BA.5-adapted vaccine or had a breakthrough infection with Omicron variants BA.1, BA.2 or BA.4/BA.5. A bivalent BA.4/BA.5 booster or Omicron-breakthrough infection induced increased Omicron-neutralization titers compared with the monovalent booster. The XBB.1.5 variant effectively evaded neutralizing-antibody responses elicited by current vaccines and/or infection with previous variants.
Topics & Concepts
Bivalent (engine)NeutralizationTiterVirologyBooster (rocketry)Neutralizing antibodyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyVaccinationChemistryMedicineImmunologyPhysicsVirusInfectious disease (medical specialty)MetalDiseaseInternal medicineOrganic chemistryAstronomySARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchViral gastroenteritis research and epidemiology